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Abstract
Background: HER2 gene copy status, and concomitant administration of trastuzumab (Herceptin), remains one of
the best examples of targeted cancer therapy based on understanding the genomic etiology of disease. However,
newly diagnosed breast cancer cases with equivocal HER2 results present a challenge for the oncologist who must
make treatment decisions despite the patient’s unresolved HER2 status. In some cases both immunohistochemistry
(IHC) and fluorescence in situ hybridization (FISH) are reported as equivocal, whereas in other cases IHC results and
FISH are discordant for positive versus negative results. The recent validation of array-based, molecular karyotyping
for clinical oncology testing provides an alternative method for determination of HER2 gene copy number status in
cases remaining unresolved by traditional methods.
Methods: In the current study, DNA extracted from 20 formalin fixed paraffin embedded (FFPE) tissue samples
from newly diagnosed cases of invasive ductal carcinoma referred to our laboratory with unresolved HER2 status,
were analyzed using a clinically validated genomic array containing 127 probes covering the HER2 amplicon, the
pericentromeric regions, and both chromosome 17 arms.
Results: Array-based comparative genomic hybridization (array CGH) analysis of chromosome 17 resolved HER2
gene status in [20/20] (100%) of cases and revealed additional chromosome 17 copy number changes in [18/20]
(90%) of cases. Array CGH analysis also revealed two false positives and one false negative by FISH due to “ratio
skewing” caused by chromosomal gains and losses in the centromeric region. All cases with complex
rearrangements of chromosome 17 showed genome-wide chromosomal instability.
Conclusions: These results illustrate the analytical power of array-based genomic analysis as a clinical laboratory
technique for resolution of HER2 status in breast cancer cases with equivocal results. The frequency of complex
chromosome 17 abnormalities in these cases suggests that the two probe FISH interphase analysis is inadequate
and results interpreted using the HER2/CEP17 ratio should be reported “with caution” when the presence of
centromeric amplification or monosomy is suspected by FISH signal gains or losses. The presence of these
pericentromeric copy number changes may result in artificial skewing of the HER2/CEP17 ratio towards false
negative or false positive results in breast cancer with chromosome 17 complexity. Full genomic analysis should be
considered in all cases with complex chromosome 17 aneusomy as these cases are likely to have genome-wide
instability, amplifications, and a poor prognosis.
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Overexpression of the HER2 protein in breast cancer is
most often the result of HER2 gene amplification on the
q arm of chromosome 17. Standard testing methods
include analysis of HER2 protein expression on the cell
membrane by IHC and/or evaluation of HER2 gene
copy number by in situ hybridiztion (ISH), most com-
monly fluorescence (FISH), but also silver (SISH) or
chromogenic (CISH), using DNA-based probes targeting
the HER2 gene locus and chromosome 17 centromere
(CEP) [1]. HER2 protein overexpression and gene ampli-
fication are prognostic markers for aggressive tumors
and predictive of response to the drugs trastuzumab
(Herceptin®) and lapatinib (Tykerb®). Accurate and defi-
nitive reporting of HER2 status is thus essential for
appropriate treatment planning in newly diagnosed
cases. Yet despite the clinical need for accurate determi-
nation of HER2 status, it is estimated that approximately
20% of current HER2 testing results may be inaccurate.
This inaccuracy has been most often attributed to multi-
ple preanalytic, analytic, and postanalytic variables
inherent to the mechanics of performing the test in a
clinical laboratory [2].
In addition to testing inaccuracies, clinicians are also
faced with treatment dilemmas resulting from cases that
are reported as “equivocal” after testing by IHC and
FISH have been completed. These cases are either 2+ by
IHC and/or have a HER2/CEP17 ratio between 1.8 and
2.2. However, there are also instances where the results
of FISH and IHC are discordant such that one test is
reported as positive (amplified) and the other as nega-
tive (unamplified). Although the numbers of these equi-
vocal and discordant cases vary widely between
laboratories, it is estimated in some studies to be as
high as 20% of cases [3].
The prevalence of inaccurate, discordant, and equivocal
HER2 results has lead to a reexamination of the adequacy
of existing methods to accurately detect copy number
changes involving the HER2 gene, particularly in the set-
ting of complex chromosome 17 rearrangements. Recent
genome wide array CGH studies have revealed that com-
plete polysomy 17, which had previously been reported
as prevalent in breast cancer, is actually a rare event
[4,5]. These and similar extended FISH studies of chro-
mosome 17 in breast cancer have additionally shown that
amplifications of the pericentromeric region are common
occurrences in both HER2 positive and HER2 negative
cases [6,7]. The complexity of these chromosome 17 peri-
centromeric rearrangements detected by both array CGH
and FISH analysis has brought into question the accuracy
of reported HER2/cep 17 ratios in cases where complex
segmental aneusomy of chromosome 17 is present. This
observation has lead to the hypothesis that unsuspected
chromosome 17 copy number changes may be contribut-
ing to the high percentage of inaccurate and equivocal
results for HER2 status in breast cancer.
The recent introduction of array-based molecular kar-
yotyping into some clinical laboratories provides an
alternative method for clinical genomic evaluation of
oncology samples [8,9]. Array-based chromosomal ana-
lysis combines the precision of locus-specific FISH with
a complete, whole-genome view of the chromosome
complement of a cell, giving clinicians both an accurate
assessment of copy number changes involving specific
genes, as well as an evaluation of the relevant chromo-
somes in the context of the entire genome. There is
growing evidence that copy number evaluation of both
the HER2 gene and chromosome 17 are of prognostic
significance in breast cancer, and that aneusomy 17 with
or without HER2 gene amplification is associated with
poor prognostic factors [10-12].
The aim of this study was to resolve the HER2 gene
and chromosome 17 status in cases of invasive ductal
carcinoma, where gene copy number and chromosome
status were equivocal and/or discordant (based on pre-
viously performed IHC and FISH analysis), by using a
clinical array CGH assay for copy number evaluation of
multiple loci along chromosome 17.
Methods
DNA Extraction from FFPE Tissues
DNA was extracted from formalin fixed, paraffin
embedded (FFPE) tumor tissues in 20 de-identified,
cases of invasive ductal carcinoma with previously evalu-
ated and unresolved HER2 and/or chromosome 17 sta-
tus due to suspected pericentromeric aneusomy (n = 2),
discordance (n = 2), and equivocal results (n = 16).
Tumors were visualized and marked on H&E stained
sections cut from the FFPE block, with targeted areas
captured by slide scraping or 4 mm punch as described
previously [13]. Following proteinase K digestion, a
minimum of 2 μg DNA was isolated using the Promega
Maxwell 16, with verification of high molecular weight
DNA by agarose gel electrophoresis.
Array-based genomic analysis
Array CGH analysis of the tumor genome was per-
formed at Combimatrix Molecular Diagnostics (CMDX)
(Irvine, CA, USA) using the Her17Array™ test, a 3039
probe whole genome bacterial artificial chromosome
(BAC) microarray with 127 probes targeting the HER2/
TOP2A amplicon, the pericentromeric regions and both
chromosome 17 arms. Tumor genomic DNA (test
DNA) and male reference DNA (as an internal control)
were differentially labeled with Alexa Fluor 555 and
Alexa Fluor 647 fluorescent dyes (Life Technologies,
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dized to the BAC arrays including four overlapping
probes for the HER2 gene, (RP11-62N23,
G248P82514H9, RP11-1065L22, RP11-94L15) and 123
additional probes for coverage of chromosome 17, the
pericentromeric region (base pairs 21.72-23.39 Mb) and
the HER2/TOP2A amplicon (base pairs 34.73-36.54 Mb
and genes PPARBP, PPP1R1B, STARD3, TCAP, PNMT,
PERLD1, GRB7, GSDML, PSMD3, CASC3, RARA,
TOP2A, SMARCE1) [14]. Hybridized microarray slides
were scanned and quantified with GenePix 4000B scan-
ner and GenePix Pro (Molecular Devices, Sunnyvale,
CA, USA). The normalized Alexa Fluor 555/647 inten-
sity ratios were computed for each of the two reactions
and plotted together for each chromosome using intern-
ally developed software (Combimatrix Molecular Diag-
n o s t i c s ,I r v i n e ,C A ,U S A ) .Ar a t i op l o tw a sa s s i g n e d
such that gains in DNA copy number at a particular
locus are observed as the simultaneous deviation of the
ratio plots from a modal value of 1.0, with the blue ratio
plot showing a positive deviation (to the right) while the
red ratio plot shows a negative deviation at the same
locus (to the left). HER2 positive versus negative status
was subjectively determined by ratio plot visualization
and objectively determined by calculating the mean of
the fluorescence intensity ratio (FIR) values for the
HER2 gene probes. A value > 1.25 was scored as positive
(amplified) and ≤ 1.25 negative (unamplified) (Figures 1a
and 1b, Table 1).
Results
Cases resolved by array CGH analysis
HER2 gene and chromosome 17 status were resolved in
20/20 (100%) of cases. Seven cases were HER2 positive
by array CGH and 13 cases were HER2 negative. There
were two cases with normal chromosome 17, one case of
monosomy 17, and one case with HER2 amplified polys-
omy 17. All other cases were found to have chromosome
17 rearrangements involving either or both chromosome
arms and the pericentromeric regions. All cases could be
resolved by subjective visualization of the chromosome
17 ratio plots, and objectively using the forward reaction
mean of the FIR values for the HER2 probes (Table 1).
HER2 positive cases and HER2 positive polysomy 17
Of the cases that were HER2 positive by array CGH,
three showed concurrent centromeric and HER2 gene
amplification (Figure 2), and three had complex
Figure 1 Reference Values.A :O b j e c t i v er e f e r e n c ev a l u e sf o rd e t e r m i n a t i o no fHER2 gene copy number, B: Subjective determination by
visualization of chromosome 17 ratio plot.
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Case Reason for Referral HER2 status by array CGH FIR Value
EQ-1 Equivocal by FISH; Polysomy? Negative 1.18
EQ-2 Equivocal by IHC and FISH Positive 1.47
EQ-3 Equivocal by IHC and FISH Positive 2.36
EQ-4 Equivocal; HER2 polyploidy? Negative 1.09
EQ-5 HER2+; HER2/centromere co-amplification? Positive 3.06
EQ-6 Equivocal by FISH pericentromeric monosomy? Negative 1.23
EQ-7 Equivocal by FISH; aneusomy? Negative 1.19
EQ-8 Equivocal by FISH; aneusomy? Negative 0.81
EQ-9 Equivocal by FISH; aneusomy? Negative 1.00
EQ-10 Equivocal by IHC and FISH Negative 0.92
EQ-11 Equivocal by IHC and FISH Negative 1.02
EQ-12 HER2+; centromeric amplification? Positive 4.23
EQ-13 HER2+ by IHC; polysomy? Positive (false - by FISH) 1.35
EQ-14 Equivocal Negative 0.81
EQ-15 Equivocal by IHC and FISH Negative 1.00
EQ-16 Discordant: IHC 1+, FISH 2.86 Negative (false + by FISH) 0.97
EQ-17 2.7 “interpret with caution due to monosomy 17” Negative (false + by FISH) 1.15
EQ-18 Resolve equivocal IHC, FISH, and OncotypeDX® Positive 1.67
EQ-19 Equivocal by IHC and FISH Negative 0.97
EQ-20 Resolve equivocal IHC, FISH and OncotypeDx® Positive 3.70
Reason for referral and array CGH findings are summarized in twenty cases of invasive ductal carcinoma. HER2 and chromosome 17 status were determined by
array CGH as determined by fluorescence intensity ratio (FIR) value. Two cases (EQ 18 and EQ 20) were also equivocal by OncotypeDX® (Genomic Health,
Redwood City, CA).
Figure 2 HER2 positive cases with ratio-skewing by FISH. HER2 positive cases showing co-amplification of the centromere and HER2 gene.
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one case low level HER2 amplification was accompanied
by chromosome 17 polysomy (Figure 3B). True unam-
plified polysomy 17 was distinguished from HER2 posi-
tive polysomy through subjective visualization of a
greater simultaneous deviation of probes at the HER2
locus, and objectively by FIR values with numerical
gains of the fluorescence intensity values for the HER2
gene that were greater than the fluorescent intensity
values for the proximal and distal 17q probes.
HER2 negative cases
Of the 13 HER2 negative cases by array CGH, five har-
bored complex chromosome 17 rearrangements (Figure
4) and three showed centromeric losses (Figure 5A).
These cases with pericentromeric losses had been
“reported with caution” as HER2 positive (n = 1) and
equivocal (n = 2) by FISH due to skewing of the HER2/
CEP17 ratio by centromeric monosomy. The remaining
HER2 negative cases had non-amplified partial polysomy
17 (n = 1), normal chromosome 17 (n = 2), and one
case of complete monosomy 17 (Figure 5B).
Chromosome 17 findings correlated to genomic
instability
Genome wide array-based chromosome analysis of the
18 cases positive for chromosome 17 abnormalities
revealed high genomic instability (> 10 significant chro-
mosomal aberrations) in 12 (67%) of cases and moderate
to low genomic instability (5-10, and < 5 aberrations) in
the other six cases. The two cases with normal chromo-
some 17 findings had low and moderate genomic
instability.
Discussion
In this study we used a clinically validated array CGH
assay to resolve HER2 gene copy number and chromo-
some 17 status in 20 cases of breast carcinoma with
equivocal or discordant results by IHC and FISH. HER2
status was determined subjectively and objectively as
positive or negative in all cases and array-based testing
additionally revealed a high incidence of chromosome
17 copy number changes involving both chromosome
arms and the centromeric region. In most cases it could
be determined that equivocal, false positive, or false
negative FISH results were due to the complexity of the
chromosome 17 abnormalities which had caused skew-
ing of the HER2/CEP17 ratio. Artificial skewing of the
Her2/CEP17 ratio occurs when the expected diploid
number of the chromosome 17 centromere probe
(D17Z1) is increased by centrome amplification or
decreased by centromere loss. Chromosome 17 centro-
mere amplification has been well described [15,16] and
recently identified as a biomarker for adjuvant anthracy-
cline benefit in early breast cancer [17]. Centromere
amplification was detected in three cases in this study:
case EQ-3 which was equivocal by FISH and cases EQ-5
and EQ-12 which were positive by FISH but had
Figure 3 HER2 positive cases with aneusomy and polysomy. A: HER2 positive cases with complex chromosome 17 rearrangements B: Case
of HER2 positive polysomy 17 which was positive by IHC and negative by FISH.
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amplification of the D17Z1 probe.
Centromeric loss was identified by array CGH in four
cases; three of these cases (EQ-6, EQ-16, EQ-17)
showed complete p arm loss with no loss of 17q, and
one case (EQ-14) had complete monosomy 17. This is
to our knowledge, the first report of loss of the chromo-
some 17 centromere in breast cancer. However, many
pathologists already recognize that CEP17 probe loss
will artificially skew the HER2 ratio towards positive and
an increasing number of cases, HER2 positive by FISH,
are being reported “with caution” when monosomy 17 is
present. For example, Case EQ-17 was reported as
HER2 positive “with caution” due to the presence of
monosomy 17. Case EQ-16 was called positive by FISH
but discordant with IHC results that were negative (1+)
Figure 4 HER2 negative cases with aneusomy. HER2 negative cases showing complex pericentromeric rearrangements.
Figure 5 HER2 negative cases with aneusomy and monosomy.A :H E R 2n e g a t i v ec a s e sw i t hc e n t r o m e r i cl o s sB :C a s es h o w i n gc o m p l e t e
monosomy 17.
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amplification of the HER2 gene in either of these cases
and confirmed that the FISH results were false positives
due to ratio skewing caused by centromeric losses.
College of American Pathologists/American Society of
Clinical Oncology (CAP/ASCO) guidelines dictate use of
the HER2/CEP17 ratio for reporting HER2 gene status by
FISH as a correction for cases where polysomy 17 is pre-
sent. However, recent array-based and extended FISH
studies of chromosome 17 have shown that true polys-
omy 17 is an exceedingly rare event in breast cancer, and
this was true not only in this study but also in previous
studies by our laboratory where no cases of true polys-
omy 17 were detected [4]. However in this study, HER2
amplified polysomy 17 was identified by array CGH in a
discordant case (EQ-13) which was HER2 positive by
both array CGH and IHC (3+) and false negative by FISH
due to skewing the HER2/CEP17 ratio (Figure 3B). It has
been proposed, and is becoming increasingly clear in
practice, that correction of HER2 gene FISH analysis with
CEP17 probes may provide misleading HER2 gene status
results in cases with centromeric gains and losses [15].
An alternative testing algorithm is therefore used by our
laboratory which encompasses the CAP/ASCO guidelines
but reflexes cases with discordant and/or equivocal
results by IHC and FISH to array-based molecular karyo-
typing (Figure 6). Application of this algorithm is
available to all pathologists, including those practicing in
most hospital or community pathology labs, through
technical only services offered by referral center labora-
tories. “Technical only” programs allow pathologists to
interpret and bill for the professional component of array
CGH testing without having to commit to the high
expenses associated with bringing the test in-house.
Conclusion
The ability of array-based molecular karyotyping assays
to analyze the entire length of chromosome 17, in paral-
lel with the HER2 gene locus, gives this newly intro-
duced clinical laboratory technique a distinct advantage
over FISH-based testing for determination of HER2 sta-
tus. Detection of genomic changes involving chromo-
some 17 is clinically relevant not only for accurate
HER2 status determination but also an important inde-
pendent prognostic marker for aggressive disease. Ana-
lysis of chromosome 17 increases the accuracy of HER2
testing and simultaneously provides additional prognos-
tic information about the tumor. In this study, taken
together, complex aberrations of chromosome 17 was
also found to be a predictor of high-risk cases likely to
have additional genomic instability and gene amplifica-
tions, well recognized biomarkers for aggressive tumor
behavior and overall reduced survival in breast cancer
[18,19]. However, assessment of these markers has not
Figure 6 Proposed algorithm for establishment of HER2 status in breast cancer samples by protein expression and genomic analysis.
IHC studies for HER2 protein expression are performed as part of the diagnostic workup and confirmed or resolved by FISH. If FISH and IHC
results are concordant, or equivocal IHC results are resolved by FISH, no further testing is done. Equivocal cases by FISH and cases with
discordant IHC/FISH results are resolved by array CGH.
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Page 7 of 8heretofore been included as part of the diagnostic and
prognostic patient workup because the clinical tools
were not available to perform high resolution genomic
analysis of FFPE tumor tissue in the clinical laboratory.
With the introduction of array-based molecular karyo-
typing, HER2 gene and chromosome 17 status can now
be accurately determined at the time of diagnosis and
full genome analysis can be considered for high-risk
patients who have tumors harboring complex chromo-
some 17 rearrangements.
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